STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [Form 4] HAEMONETICS CORP Insider Trading Activity

Haemonetics (HAE) CEO receives 78,344 RSUs and has shares withheld for taxes

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Haemonetics Corp President & CEO Christopher Simon reported compensation-related equity activity. He received an award of 78,344 shares of common stock in the form of restricted stock units that vest over three years. On the same date, 9,681 shares were withheld to cover tax obligations tied to previously vesting RSUs, and his reported direct holdings after these transactions were in the hundreds of thousands of shares.

Positive

  • None.

Negative

  • None.
Insider Simon, Christopher
Role President & CEO
Type Security Shares Price Value
Tax Withholding Common Stock 9,681 $56.29 $545K
Grant/Award Common Stock 78,344 $0.00 --
Holdings After Transaction: Common Stock — 366,360 shares (Direct, null)
Footnotes (1)
  1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
RSU award 78,344 shares Common stock RSUs granted on 2026-05-15
Tax withholding shares 9,681 shares Shares withheld for tax obligations at $56.29 per share
Withholding price $56.29 per share Value used for tax-withholding disposition
Holdings after RSU grant 444,704 shares Direct common stock holdings following the award entry
Holdings after tax withholding 366,360 shares Direct common stock holdings following tax-withholding disposition entry
ESPP purchase 497 shares Shares purchased under 2007 Employee Stock Purchase Plan on 2026-04-30
RSU vesting pattern 40% / 40% / 20% Annual vesting over three anniversaries of grant date
restricted stock units ("RSUs") financial
"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Purchase Plan financial
"497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Long-Term Incentive Compensation Plan financial
"RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"
tax obligations financial
"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units"
contingent right financial
"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Simon, Christopher
(Last)(First)(Middle)
125 SUMMER STREET
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026F9,681(1)D$56.29366,360(2)D
Common Stock05/15/2026A78,344(3)A(4)444,704(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. This number includes unvested RSUs previously reported as well as 497 shares purchased by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on April 30, 2026.
3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
/s/ Thomas V. Powers, attorney-in-fact for Mr. Simon05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity award did Haemonetics (HAE) CEO Christopher Simon report on this Form 4?

Christopher Simon reported a grant of 78,344 shares of common stock in the form of restricted stock units. These RSUs were issued under Haemonetics’ long-term incentive plan and represent a compensation award rather than an open-market purchase.

How do the new Haemonetics (HAE) RSUs for the CEO vest over time?

The CEO’s new RSUs vest in three annual installments. Forty percent of the total award vests on the first anniversary of grant, another forty percent on the second anniversary, and the remaining twenty percent on the third anniversary, subject to the plan’s conditions.

Why were 9,681 Haemonetics (HAE) shares disposed of in this insider filing?

The 9,681 shares were withheld to satisfy tax obligations on vesting RSUs. This tax-withholding disposition is a non-market event where shares are delivered to cover taxes owed on previously granted restricted stock units.

>How many Haemonetics (HAE) shares did Christopher Simon hold after these transactions?

The filing shows hundreds of thousands of shares directly held after the reported transactions. One line reports 444,704 shares following the RSU grant, while another shows 366,360 shares following the tax-withholding disposition, reflecting different steps in the sequence.

What does each Haemonetics (HAE) RSU in this award represent?

Each RSU represents a contingent right to receive one share of Haemonetics common stock when vested. Once vesting conditions are met, the company issues an equivalent number of shares to the reporting person under the plan.

Did the Haemonetics (HAE) CEO buy any shares through an employee stock purchase plan?

The filing notes that 497 shares were purchased under Haemonetics’ 2007 Employee Stock Purchase Plan. This purchase is included in the total number of shares reported as held by Christopher Simon, alongside unvested RSUs.